Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity

S Garciaz, D Coso, JM Schiano de Collela… - Bone Marrow …, 2016 - nature.com
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for patients with relapsed aggressive non-HodgkinLs lymphoma (NHL). 1, 2 …
被引用次数：39 相关文章

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity

S Garciaz, D Coso, JMS de Collela… - Bone marrow …, 2016 - pubmed.ncbi.nlm.nih.gov
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an
increasing risk of renal toxicity Bendamustine-based conditioning for non-Hodgkin lymphoma …

[引用][C] Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.

S Garciaz, D Coso, JM Schiano de Collela… - Bone Marrow …, 2015 - europepmc.org
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation:
an increasing risk of renal toxicity. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.

S Garciaz, D Coso, JMS de Collela… - Bone Marrow …, 2016 - go.gale.com
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL).(1, 2) …

[引用][C] Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity

S Garciaz, D Coso, JS De Collela… - Bone Marrow …, 2016 - Nature Publishing Group